title: CD95-mediated tumor recognition by CD4+ effector cells in a murine mammary model.
abstract: The authors examined cellular mechanisms involved in anti-tumor reactivity induced by the murine MT-9G1 mammary tumor line, which was transduced to secrete granulocyte macrophage-colony-stimulating factor (GM-CSF). Compared with the parental MT-901 tumor, MT-9G1 subcutaneous tumors elicited an influx of CD4+ cells and dendritic cells. Secondary in vitro activation of tumor-draining lymph node cells with anti-CD3 and interleukin-2 resulted in effector cells that can mediate regression of established pulmonary metastases after adoptive transfer. In vivo depletion of T-cell subsets showed that tumor regression required CD4+ tumor-draining lymph node cells rather than CD8+ cells. The activated CD4+ cells expressed CD95L and mediated lysis of CD95+ MT-901 tumor cells, which were major histocompatibility complex class II negative. The CD4+ cells also released GM-CSF in response to tumor stimulation. A Fas fusion protein inhibited tumor lysis and GM-CSF release by the CD4+ cells. These studies document an alternate pathway by which CD4+ immune cells may recognize major histocompatibility complex class II-deficient tumors in which CD95L-bearing T cells induced an anti-tumor response mediated via CD95L:CD95.
authors.affiliation: National Cancer Center Hospital East, Tokyo Women's Medical College, Japan.
authors.forename: E
authors.initials: E
authors.lastname: Aruga
authors.forename: K
authors.initials: K
authors.lastname: Tanigawa
authors.forename: A
authors.initials: A
authors.lastname: Aruga
authors.forename: H
authors.initials: H
authors.lastname: Arai
authors.forename: J W
authors.initials: JW
authors.lastname: Smith
authors.forename: B J
authors.initials: BJ
authors.lastname: Nickoloff
authors.forename: G J
authors.initials: GJ
authors.lastname: Nabel
authors.forename: A E
authors.initials: AE
authors.lastname: Chang
mesh_terms: D019264:Adoptive Transfer; D000818:Animals; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology* / Q000378:metabolism; D016207:Cytokines / Q000378:metabolism; D003602:Cytotoxicity, Immunologic; D053222:Fas Ligand Protein; D005260:Female; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000378:metabolism; D008198:Lymph Nodes / Q000276:immunology / Q000378:metabolism / Q000473:pathology; D008325:Mammary Neoplasms, Experimental / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D008562:Membrane Glycoproteins / Q000096:biosynthesis; D051379:Mice; D008807:Mice, Inbred BALB C; D009368:Neoplasm Transplantation; D019014:fas Receptor / Q000096:biosynthesis / Q000502:physiology*
chemical_list: D016207:Cytokines; D053222:Fas Ligand Protein; C505658:Fasl protein, mouse; D008562:Membrane Glycoproteins; D019014:fas Receptor; D016178:Granulocyte-Macrophage Colony-Stimulating Factor